Bleeding or Hemostasis Flashcards

1
Q

What is Virkhoff’s Triad?

A
  1. Venous stasis (post-MI, stroke, or post-operation) - inhibited removal of coagulation factors
  2. Hypercoaguability state - multi-factorial and multiplicative or additive: Genetic (Factor V Leiden (5% of pop.), immobolization, age, surgery, trauma, neoplasms, hormone related, heart failure, blood dycrasias
  3. Endothelial Damage - exposes endothelium to prompt hemostasis - less inhibition of coagulation and decreased fibrinolysis
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What are the physical exam features of primary hemostatic bleeding disorders?

And what are causes of those bleeding disorders?

A

Physical Exam

bleeding from mucocutaneous tissues, bleeding from superficial areas –> petechia, epitaxis, purpura, mucous membranes, excessive periods

Causes

  • thrombocytopenia
  • VWD
  • platelet function disorders (drug acquired causes)
  • vascular abnormalities
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What are the common laboratory tests for primary hemostatic bleeding disorders?

A
  1. Platelet aggregation studies - if func. of plt in Q
  2. Closure time - if func. of plt in Q
  3. CBC and smear
  4. VWF studies
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What are the clinical features of the secondary hemostatic disorders?

A
  1. hematomas
  2. muscle bleeding
  3. hemathrosis
  4. bleeding is delayed and prolonged, common after surgery
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Laboratory Tests for Secondary hemostatic diseases?

A
  • aPTT (activated partial thromboplastin time)
    • Measures the intrinsic pathway
      • Factors 8,9,10,11,12
  • PT (prothrombin time or INR - developed to monitor warfarin)
    • Factor VII

Can have elevated PTT and PT if common pathway (X —V—-> II)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What are the three mechanisms that produce thrombocytopenia?

A
  1. Increased destruction - autoimmune or not?
  2. Descresed production - look at the bone marrow
  3. Sequesteration - look at splenomegaly
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

List the platelet production problems

A
  • Descreased megakaryopoesis
    • Leukemias or displacement via cancer, aplastic anemias, toxic suppression (chemotherapy)
  • Ineffective
    • nutritional megaloblastic anemia - vitamin b12 or folate
      • Folate inhibitor
      • Congentital
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

List the platelet destruction problems

A
  • Immune
    • allo - post transfusion
    • auto - ITP, usually with SLE or CLL
  • Drug induced HIT (heparin induced…)
  • Non-immune
    • Sepsis, DIC, TTP, HUS, HHELP
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

List differences between acute and chronic ITP

A
  • Chronic
    • Adults, severe bleeding risk when platelets < 30, which indicates treatment of immuno suppression (corticosteroids first line, IVIG also can work, anti-Rho, splenoctomy is second line)
  • Acute
    • Kids
    • 80% will resolve without treatment
    • serious bleeding is rare
    • Post-viral
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Describe HIT

A

Heparin induced thrombocytopenia

  • Drug reaction, less common with LMWH
  • administer protamine to counteract heparin and change drugs immediately
  • thrombosis
  • skin necrosis at site of injection
  • 50% fall in plts
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What is the most common causes of acquired platelet function disorder?

A

COX-1 inhibitor (ASA)

  • stops the releases of thromboxane A2
  • Also, there are systemic illnesses and hematological manifestations that causes function disorders*
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

List three congentital platelet disorders (rare or common?)

A
  • Glanzzman’s Thromboesthemia
  • Bernard Soulier Syndrome
  • Gray Platelet Syndrome
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What does vitamin K do?

A

Allows the carboxylation of factors II, VII, IX, and X, which allows these clotting factors to bind the phospholipids on the surface of platelets

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

List the causes of vitamin K deficiency

A
  1. Diet
  2. Malabsorption (Celiac’s, IBD)
    1. And disorders of fat malabsorption (pancreatic or bile disorders)
  3. Too much Vitamin A and E
  4. Antibiotics – impaired normal flora
  5. Drugs – warfarin
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What causes hemorrhagic disease of the newborn?

A

Insufficient vitamin K

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Describe how liver disease can result in coagulopathy

A
  • Most of the clotting factors are produced in the liver
    • Exceptions are VIII (endothelial cells) and VWF (endothelial cells or megakaryocytes)
  • Acute liver disease will have a prolonged PT
    • VII has the shortest half-life and is the first to be affected
  • Chronic liver disease will have prolonged PT/PTT
17
Q

What is the purpose of INR?

A

INR was developed to make dose-adjustments for warfarin in order descrease the likelihood of bleeding or thrombotic events

Standardized PT

18
Q

What is the DDX for elevated PTT/normal PT?

A
  • X-linked deficiencies
    • Hemophilia A (VIII)
    • Hemophilia B (IX)
  • Autosomal Recessive
    • Factor XI
  • Autosomal Dominant
    • VWF
  • Antiphospholipid antibodies
  • Heparin
  • Factor VIII inhibitor
19
Q

Describe the pathophysiology of antiphospholipid antibodies

A

Lupus type inhibitor is the most common one

  • Inhibit the phospholipid (high PTT), but does not interupt the physiological clotting cascade
  • In fact, it actually leads to thrombosis
  • Other complications include miscarriages
  • Do a mixing study to rule-out
20
Q

VWF functions?

A
  1. Binds platelet - platelet
  2. Platelet - endothelium
  3. binds VIII (part of fibrin clot formation!)
21
Q

VWD

  1. 3 types
A

Type 1 - deficiency, equal low VWF antigen and activity

  • Low or normal VIII

Type 2 - lower activity of VWF (function, many subtypes)

  • low or normal VIII

Type 3 - extremely low antigen and activity, full deficiency

  • < 10% of VIII
22
Q

Treatment of VWD

A
  • DDAVP (desmopression)
    • Stimulates release of VWF from subendothelial cells
    • Works well for type 1 (unless severe), some type 2, but not type 3
  • VWF/VIII replacement therapy
    • Needed in type 3, severe type 1
    • IV virally inactivated
    • Indicated post or pre-operatively or other indication of bleeding
  • anti-fibrolytics
    • adjuct
    • Used alone only in mild symptomatic VWF disease
    • contra-indicated with hematuria
23
Q

Polycythemia Vera

A
  • stem cell disorder
  • elevated RBC mass +/- increase WBC and platelets
  • symptoms due to high red cells
  • bleeding and thrombotic ecvents
  • erythomelalgia - burning in hands, feet and erythema
  • pruitus
  • gout, plethora on face, palms
  • splenomegaly and hepatosplenomegaly is common
  • LOOK for hemoglobin over 165 (W) or 185 (M) and JAK2 mutation. Plus minor criteria (bone marrow biopsy with hypercellularikty, low EPO levels, endogenous erythroid colony formation in vitro)

Treatment

  • phelbotomy to keep hemtocrit < 45%
  • ASA to prevent thrombosis
  • hydroxyurea (if refractory to phlebotomy)
  • allopurionol and antihistamines for symptoms

Complications

  • Bleeding or thrombosis, progression to AML
  • median surival is 10-20 yrs
24
Q

List the Well’s Score criteria

A
  1. Stasis (>3 day in hospital)
  2. Prior Surgery (< 6 months)
  3. Active Cancer
  4. Prior DVT
  5. Calf swelling (>3cm)
  6. Leg swelling
  7. Pitting edema
  8. Collateral superficial veins
  9. localized tenderness

2 or MORE = DVT likely

25
Q

Simplified Well’s score for PE

A
  1. Symptoms of DVT = 3
  2. No other Dx = 3
  3. Immobilization = 1.5
  4. Malignancy = 1
  5. Hemoptysis = 1
  6. Prior DVT = 1.5
  7. Tachycardic (>100) = 1.5

PE suspected if 4 or >

26
Q

What are the 2 primary options for imaging a VTE?

A
  1. CT pulmonary angiography - visualizes the blood vessels
  2. Compression ultrasonography

Also available

  1. Ventilation and perfusion (V/P) when CTPA is contraindicated (preg., renal insufficiency, reaction to contrast medium)
27
Q

How can you tell a PE is really bad?

A
  1. Right ventricular strain
  2. elevated BNP and troponin
28
Q

List the common/serious side effects of heparin, as well as its mechanism of action and monitoring

A
  • Heparin is monitored with aPTT (1.5 - 2.5 is ideal)I
  • heparin is often started at hospital in VTE cases
    • Risk of bleeding, especially with prior surgery
    • Major risk is heparin induced thrombocytopenia (HIT), which results in more clotting! Platelets are being used up, hence the penia
      • argatroban is an anti-thrombin which is indicated during HIT
  • Heparin is an indirect anti-thrombin activator, it helps X and IX come together with anti-thrombin
  • LMWH is a better alternative, can be taken orally, preferred in cancer and pregancy, no need for monitoring, lower risk of HIT and bleeding
29
Q

Outline the basic plan behind seeing a VTE patient as well as describe warfarin’s mechanism of action

A
  • Do the Well’s score, D-dimer if unlikely
  • CT or compression ultrasonography

ACUTE

  • heparin, oral Xa inhibitors (rivaroxaban), LMWH (preg. or active cancer)
  • Monitor the aPTT
  • If extremely serious, may need to use fibrinolytics
  • IVC shunt not really used, only in cases where fibrinolytics are contraindicated (high risk of bleeding)

CHRONIC

  • Warfarin (need to overlap with heparin for first 5 days because of initital hypercoagulable state from decreased protein C)
    • inhibits II, VII, IX, and X via inhibiting vitamin K glycosylation of these factors
    • INR monitoring required
  • LMWH
  • Oral Xa inhibitors
  • Direct thrombin inhibitors
    • dabigitran
30
Q

What is Hydroxurea used for?

A
  1. Sickle cell disease (increases Fetal hemoglobin, helpful during acute chest syndrome)
  2. Myeloproliferative syndromes, especially ET and PV
  3. Formally used in CML, now replaced by GLEEVEC
  4. HIV/AIDS
31
Q
A